Collectively, these studies demonstrate that Plasmodium-specific IgM+ MBCs are high-affinity, pluripotent early responders to malaria rechallenge that might provide a critical stop gap until IgG antibodies are generated and should therefore be considered in vaccine strategies. This evidence concerns the gene CD40LG and malaria.